Practical treatment guidance for cancer-associated thrombosis-Managing the challenging patient: A consensus statement

被引:9
作者
Musgrave, Kathryn M. [1 ]
Power, Kieron [2 ]
Laffan, Mike [3 ]
O'Donnell, James S. [4 ]
Thachil, Jecko [5 ]
Maraveyas, Anthony [6 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England
[2] Swansea Bay Univ, Singleton Hosp, Hlth Board, Swansea SA2 8QA, W Glam, Wales
[3] Hammersmith Hosp, Imperial Coll, Ctr Haematol, London W12 0NN, England
[4] Royal Coll Surgeons Ireland, Irish Ctr Vasc Biol, Dublin, Ireland
[5] Manchester Univ Hosp, Manchester, Lancs, England
[6] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England
关键词
Algorithm; Cancer-associated thrombosis; Consensus; Guidelines; Treatment; DIRECT ORAL ANTICOAGULANTS; RECURRENT VENOUS THROMBOEMBOLISM; MOLECULAR-WEIGHT HEPARIN; CHRONIC KIDNEY-DISEASE; P-GLYCOPROTEIN; DRUG-INTERACTIONS; OBESE-PATIENTS; BODY-WEIGHT; INTRACRANIAL HEMORRHAGE; CYTOCHROME-P450; 3A4;
D O I
10.1016/j.critrevonc.2022.103599
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer-associated thrombosis (CAT) is a leading cause of death amongst people with cancer. Treatment decisions have become increasingly complex with the introduction of direct oral anticoagulants and existing guidelines are limited to evidence from patients meeting stringent trial-entry criteria. To assist decision making for healthcare professionals managing CAT in challenging 'real-world' situations, an expert working group of clinicians from oncology, haematology and pharmacology convened over a series of virtual meetings between September 2020 and January 2021 to catalogue the most challenging clinical problems and define consensus recommendations. Clinical problems were divided amongst the group members according to their areas of expertise, with each reviewing the literature and writing their recommendations. Using a web-based file-sharing platform, each contribution was reviewed until consensus was reached. Each clinical problem is discussed; these include managing gastrointestinal impairment, renal impairment, liver impairment, increased risk of bleeding, extremes of body weight, drug interactions, anticoagulation beyond the initial six months and managing recurrent thrombosis. A user-friendly, practical, colour-coded algorithm was produced to help guide clinical decision-making in CAT. Red highlights decision steps where shared decision making, such as with the multi-disciplinary team, is rec-ommended. Amber steps reflect uncertainty of existing evidence. Multiple amber steps per patient warrant increased caution. Making anticoagulation decisions in people with cancer is challenging; it is important that healthcare pro-viders can discuss where there is a lack of evidence and ensure that patient preference is given priority. This algorithm and consensus recommendations are a useful tool to guide these complex discussions.
引用
收藏
页数:13
相关论文
共 99 条
[1]   Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer [J].
Agnelli, Giancarlo ;
Becattini, Cecilia ;
Meyer, Guy ;
Munoz, Andres ;
Huisman, Menno, V ;
Connors, Jean M. ;
Cohen, Alexander ;
Bauersachs, Rupert ;
Brenner, Benjamin ;
Torbicki, Adam ;
Sueiro, Maria R. ;
Lambert, Catherine ;
Gussoni, Gualberto ;
Campanini, Mauro ;
Fontanella, Andrea ;
Vescovo, Giorgio ;
Verso, Melina .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (17) :1599-1607
[2]   Investigation of Direct-Acting Oral Anticoagulants and the Incidence of Venous Thromboembolism in Patients Weighing ≥120 kg Compared to Patients Weighing <120 kg [J].
Aloi, Kristin G. ;
Fierro, Joseph J. ;
Stein, Bradley J. ;
Lynch, Sullivan M. ;
Shapiro, Robert J. .
JOURNAL OF PHARMACY PRACTICE, 2021, 34 (01) :64-69
[3]  
Apixaban, 2011, SUMMARY PRODUCT CHAR
[4]  
Aprepitant Summary of Product Characteristics, 2018, 80 MG 125 MG HARD CA
[5]   Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review [J].
Ballestri, Stefano ;
Capitelli, Mariano ;
Fontana, Maria Cristina ;
Arioli, Dimitriy ;
Romagnoli, Elisa ;
Graziosi, Catia ;
Lonardo, Amedeo ;
Marietta, Marco ;
Dentali, Francesco ;
Cioni, Giorgio .
ADVANCES IN THERAPY, 2020, 37 (05) :1910-1932
[6]   Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH [J].
Bannow, B. T. Samuelson ;
Lee, A. ;
Khorana, A. A. ;
Zwicker, J. I. ;
Noble, S. ;
Ay, C. ;
Carrier, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (06) :1246-1249
[7]   Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review [J].
Bannow, Bethany R. Samuelson ;
Lee, Agnes Y. Y. ;
Khorana, Alok A. ;
Zwicker, Jeffrey I. ;
Noble, Simon ;
Ay, Cihan ;
Carrier, Marc .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2018, 2 (04) :664-669
[8]   Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers [J].
Bashir, Babar ;
Stickle, Douglas F. ;
Chervoneva, Inna ;
Kraft, Walter K. .
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2018, 11 (06) :590-596
[9]   Renal Impairment, Recurrent Venous Thromboembolism and Bleeding in Cancer Patients with Acute Venous ThromboembolismAnalysis of the CATCH Study [J].
Bauersachs, Rupert ;
Lee, Agnes Y. Y. ;
Kamphuisen, Pieter W. ;
Meyer, Guy ;
Janas, Mette S. ;
Jarner, Mikala F. ;
Khorana, Alok A. .
THROMBOSIS AND HAEMOSTASIS, 2018, 118 (05) :914-921
[10]   Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A [J].
Bekaii-Saab, TS ;
Perloff, MD ;
Weemhoff, JL ;
Greenblatt, DJ ;
von Moltke, LL .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2004, 25 (07) :283-289